30Oct 2023
Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators

Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators

Hidradenitis suppurativa (HS) treatments, including anti-TNF agents and IL-17 inhibitors, have shown potential, yet concerns about infection risks persist. A systematic review of 24 studies (1,696 patients) revealed a 24.2% incidence of mild respiratory and skin infections. Anti-IL17 treatment correlated with the highest infection rate at 33.6%, but risk elevation wasn't significant (0.99, 95% CI: 0.86–1.14). Serious infections were rare (0.39% for anti-IL17, 0.03% for anti-TNF), and opportunistic infections were infrequent, with reported cases of oral candidiasis, cryptosporidiosis, and Blastocystis hominis infection.

  • #dermatology

Like

Save

Share